The following information was compiled in August 2024 and is subject to change as new research is conducted and as new information becomes available:

Description: 5,6-Dichloro desmethylchlorphine is a novel synthetic opioid with structural similarity to other benzimidazolones (e.g., brorphine, chlorphine, etc.). 5,6-Dichloro desmethylchlorphine (also known as SR-17018) was first evaluated as a potential mu opioid receptor agonist via bias factor calculations in 2017. 5,6-Dichloro desmethylchlorphine was first identified by our laboratory in a sample designated for recreational use in May 2024 and was confirmed in June 2024 after acquiring standard reference material.

Sample Source: Unknown (United States)

Sample Appearance: White powder

Pharmacology: 5,6-Dichloro desmethylchlorphine is described as a biased mu opioid receptor agonist with less respiratory depression compared to other opioid agonists. 5,6-Dichloro desmethylchlorphine was determined to have similar potency to morphine with a half-life of 6-8 hours.

Toxicology: 5,6-Dichloro desmethylchlorphine has not been identified in toxicology cases at the CFSRE.

Drug Materials: 5,6-Dichloro desmethylchlorphine has been detected in one drug material at the CFSRE.

Demographics / Geographics: The drug material sample containing 5,6-dichloro desmethylchlorphine for originated from the United States.

Legal Status: 5,6-Dichloro desmethylchlorphine is not currently a scheduled drug in the United States.

Class: Opioid
 Appearance: White powder
 Formula: C19H18Cl3N3O
 MW: 410.7
 [M+]: 409  [M+H]+: 410.0588
 IUPAC: 5,6-dichloro-3-[1-[(4-chlorophenyl)methyl]-4-piperidyl]-1H-benzimidazol-2-one
 Report Date: August 23, 2024